Omniose Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2022

Location

St. Louis MO US

Primary Industry

Healthcare

About

Based in Missouri, US, and founded in 2022, Omniose, aka VaxNewMo is an early-stage biotechnology company that is developing polysaccharide conjugate vaccines against significant bacterial threats. Christian Harding, Christine Szymanski, and Mario Feldman are the co-founders of the company. As of 2022, Timothy Cooke is the CEO of the company. In October 2022, Omniose received USD 3.6 million in grant funding from the National Institutes of Health. The company develops a bioconjugate vaccine platform that allows the enzymatic attachment of any bacterial polysaccharide (sugar) antigen to engineered carrier proteins within a single E. coli cell. The firm is developing polysaccharide-protein conjugate vaccines against K. pneumoniae using its patented bioconjugation platform. The organization plans to use the October 2022 funding for the development of a Klebsiella pneumoniae vaccine and IND-enabling studies of bioconjugate vaccines.

Current Investors

The National Institutes of Health

Request a demo to show more

Primary Industry

Healthcare

Sub Industries

Biopharmaceuticals

Website

www.omniose.com

Company Stage

Angel & Seed

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.